Ernexa Therapeutics Inc. Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)
Ernexa Therapeutics Inc. (ERNA) had Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) of $1.56 million as of 2013-12-31, per its 10-K filed 2014-03-31.
Discontinued › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:LineOfCreditFacilityAmountOutstanding · last filed 2014-03-31
- 2013-12-31: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $1.56M.
| Period end | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) |
|---|---|
| 2013-12-31 | $1.56M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |